These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 8725881)
1. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881 [TBL] [Abstract][Full Text] [Related]
2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854 [TBL] [Abstract][Full Text] [Related]
3. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560 [TBL] [Abstract][Full Text] [Related]
4. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Zhang Y; Yu D; Xia W; Hung MC Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095 [TBL] [Abstract][Full Text] [Related]
5. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Yu D; Wolf JK; Scanlon M; Price JE; Hung MC Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034 [TBL] [Abstract][Full Text] [Related]
6. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456 [TBL] [Abstract][Full Text] [Related]
7. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307 [TBL] [Abstract][Full Text] [Related]
8. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Kao MC; Liu GY; Chuang TC; Lin YS; Wuu JA; Law SL Oncogene; 1998 Jan; 16(4):547-54. PubMed ID: 9484845 [TBL] [Abstract][Full Text] [Related]
9. Basic science of HER-2/neu: a review. Hung MC; Lau YK Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Chang JY; Xia W; Shao R; Hung MC Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978 [TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184 [TBL] [Abstract][Full Text] [Related]
12. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737 [TBL] [Abstract][Full Text] [Related]
13. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517 [TBL] [Abstract][Full Text] [Related]
14. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu. Wen CC; Cheng SA; Hsuen SP; Huang YL; Kuo ZK; Lee HF; Kuo CH; Du JL; Wang WB Cancer Res; 2006 Jun; 66(11):5847-57. PubMed ID: 16740724 [TBL] [Abstract][Full Text] [Related]
15. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Xing X; Wang SC; Xia W; Zou Y; Shao R; Kwong KY; Yu Z; Zhang S; Miller S; Huang L; Hung MC Nat Med; 2000 Feb; 6(2):189-95. PubMed ID: 10655108 [TBL] [Abstract][Full Text] [Related]
16. The role of the HER-2/neu oncogene in gynecologic cancers. Cirisano FD; Karlan BY J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816 [TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319 [TBL] [Abstract][Full Text] [Related]
18. The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. Lin YC; Peng JM; Wang WB Oncogene; 2000 May; 19(22):2704-13. PubMed ID: 10851070 [TBL] [Abstract][Full Text] [Related]
19. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Xing X; Zhang S; Chang JY; Tucker SD; Chen H; Huang L; Hung MC Gene Ther; 1998 Nov; 5(11):1538-44. PubMed ID: 9930307 [TBL] [Abstract][Full Text] [Related]
20. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]